Clinical Outcomes and Global Epidemiology -Data Coordinating Center

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-07-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection. Secondary Objectives include the following: To determine the impact of inactive empiric antimicrobial therapy, defined as receipt of empiric antimicrobial therapy with no in vitro activity against the offending isolate for at least 24hrs, on the outcome (end points defined below) of patients with Acinetobacter bloodstream infection. To determine the impact of carbapenem resistance and pan-drug resistance (defined as resistance to all antimicrobials except colistin and/or tigecycline if these agents were tested) on the outcome of patients with Acinetobacter bloodstream infection. To assess the efficacy of varying definitive therapies on the outcome of patients with Acinetobacter bloodstream infection. To characterize the molecular epidemiology of Acinetobacter on a global level, as determined by pulsed-field gel electrophoresis (PFGE) and other techniques, and to assess whether patient outcomes are clonally related and to characterize the mechanisms of resistance in Acinetobacter on a global scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Correlation Between Antibiotic Resistance and Incidence of Sepsis in Community Acquired Pneumonia

NCT05606627

Community-acquired Pneumonia Antibiotic Resistance Sepsis

UNKNOWN

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

NCT02719769

Bacteremia Fungemia

COMPLETED

Antibiotic Stewardship in AECOPD Through CRP-Guided Management

NCT05286918

Acute Exacerbation of COPD Lung Diseases Lung Diseases, Obstructive +2 more

NOT_YET_RECRUITING NA

Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients

NCT04674410

Covid19 Coronavirus Infection Pneumonia

WITHDRAWN

Outcomes of Patients Not Responding to Antibiotics in the Community

NCT00245427

Sinusitis Bronchitis, Chronic Pneumonia, Bacterial

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Medical records will be reviewed and information collected from charts to assess for independent predictors of in-hospital mortality (up to 28 days) in patients with Acinetobacter bloodstream infection. 24 sites will participate and all information will be loaded into a password protected database.